B2Broker: B2BinPay Joins Forces with Ledger to Offer Customized Limited Edition Hardware Wallets
19.7.2023 20:00:00 EEST | Business Wire | Press release
The collaboration between B2BinPay and Ledger, two leading companies in their industries, marks a significant achievement. Through this innovative partnership, customers can now access an exclusive offering: a branded Ledger Nano X hardware wallet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230719252053/en/
B2BinPay Joins Forces with Ledger to Offer Customized Limited Edition Hardware Wallets (Graphic: Business Wire)
This limited edition wallet showcases a distinctive crypto-processing design and prominently displays the B2BinPay logo. The joint effort of these two companies combines their expertise to deliver an outstanding product for customers.
Two types of clients can access these exclusive ledgers:
1. New merchants and enterprise clients;
2. Existing loyal customers who have been supporting B2BinPay.
These branded ledgers serve as a disclosure of appreciation for their ongoing support.
To offer customers a smooth experience, B2BinPay will supply personalized promo codes for acquiring their hardware wallets. These distinct codes can be entered on Ledger's official website on the specified collaboration page, allowing individuals to secure their unique devices effortlessly.
Please note that only 1000 units of these branded wallets are available. This limited quantity underscores these devices' exclusivity and exceptional worth, making them highly coveted by cryptocurrency enthusiasts and collectors.
Advantages of Ledger
Ledger's reputable multicurrency devices have gained the trust of individuals seeking a secure way to store their cryptocurrency private keys offline. These devices provide unbeatable protection against hackers while offering simplicity in managing assets and ensuring transaction transparency.
The partnership between B2BinPay and Ledger allows clients to access the industry's leading solutions for crypto storage. With these reliable hardware wallets, clients can confidently diversify their portfolios and efficiently manage their assets while maintaining the highest level of security.
Through the collaboration of B2BinPay and Ledger, clients are guaranteed access to top-tier storage solutions. This empowers them to navigate the cryptocurrency world confidently and gives them enhanced control over their digital assets, providing peace of mind.
Advantages of B2BinPay
As an all-in-one solution for secure cryptocurrency transactions, B2BinPay empowers businesses to send, receive, convert, and accept crypto assets efficiently. With support for major cryptocurrencies, clients can easily consolidate their digital assets into their preferred fiat, coin, or stablecoin format.
The collaboration with Ledger strengthens its commitment to delivering reliable and efficient solutions for managing crypto assets. This partnership inspires confidence in their ability to meet the evolving needs of their valued clients while staying at the forefront of advancements in the FinTech industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719252053/en/
Contact information
+44 2080 688 636
pr@b2broker.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom